Loading stock data…
INCY
$103.23+2.59 (+2.57%)
Market ClosedLast close Jun 9
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incyte Corporation in the Healthcare sector is trading at $103.23 with a market capitalization of $19.3B. Wall Street consensus targets $108.83 (23 analysts), implying a +5.4% move over the next 12 months. The stock is currently near its 52-week high of $112.29, remaining 7.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$103.23
Potential Upside
68.6%
Whystock Fair Value$174.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target$108.83+5.4%
Range$71.00 – $140.00
Fundamentals
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycyth...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.33B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.66
Beta
Defensive asset. Lower volatility than the S&P 500.
0.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.46%
Volume
Today's trading volume
2.21M
Recent News
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and
Incyte To Acquire Vega Therapeutics For Up To $2 Billion
Incyte (INCY) agreed to acquire Star Therapeutics unit Vega Therapeutics in a deal worth up to $2 bi
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company’s hematology portfolio into bleeding disorders.